BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy

Reuters
10 Mar
BRIEF-Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy

March 10 (Reuters) - Arrowhead Pharmaceuticals Inc ARWR.O:

  • ARROWHEAD PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM PART 2 OF PHASE 1/2 STUDY OF ARO-C3 IN PATIENTS WITH IGA NEPHROPATHY

  • ARROWHEAD PHARMACEUTICALS INC - ARO-C3 GENERALLY WELL-TOLERATED IN PATIENTS WITH IGAN

  • ARROWHEAD PHARMACEUTICALS INC - NO SERIOUS OR SEVERE TREATMENT EMERGENT ADVERSE EVENTS REPORTED

Source text: nBw3yHhH8a

Further company coverage: ARWR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10